secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001193125-26-079286
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 1.01, 9.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences CFO Richard Bartram resigns; John Smither named interim CFO
---------------------------------------------------------------------------

- CFO Richard Bartram resigns effective March 15, 2026; will serve as consultant post-resignation.
- John Smither appointed Interim CFO effective March 16, 2026; base salary $325k, target bonus 40%, $25k sign-on.
- Lease entered for 13,642 sqft office/lab in Burlington, MA; aggregate base rent ~$3.4M over 4-year term.
- Departure not due to dispute; search for permanent CFO underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526079286/0001193125-26-079286-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000119312526079286/mbx-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-079286

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer